Searched for
COVID ORAL DRUG
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Laurus Labs inks pact with MPP to produce molnupiravir"We are happy to sign an agreement to manufacture the oral COVID-19 antirviral medication, which is an urgent need of the hour, this is one...
- Lupin launches Molnulup for COVID-19 treatmentMolnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 pati...
- Pfizer Inc signs $5.3 billion COVID-19 pill deal with US govtThe company earlier this month said the drug cut by 89% the chance of hospitalization or death for adults at risk of severe disease. The tr...
- India's Everest Organics starts making ingredient for Merck's COVID-19 pillThe Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...
- A new oral antiviral drug for COVID-19 is being tested in humans - can it make a difference?One promising drug that could improve things is molnupiravir, an antiviral that's moving into the final stages of testing in humans. Resear...
- Bharat Parenterals gets DCGI nod for favipiravir oral suspensionThe company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parente...
- Ivermectin: Drug that Goa recommends to all above 18 to combat Covid-19While the World Health Organisation (WHO) has warned against the general, unchecked use of Ivermectin, a study published in the American Jo...
- DRDO’s new oral drug to reduce dependence on oxygenThe Institute of Nuclear Medicine and Allied Sciences, a DRDO lab, worked in partnership with Dr Reddy’s Laboratories to develop the drug, ...
- DCGI approves anti-COVID drug developed by DRDO for emergency useAccording to Defence Research and Development Organisation (DRDO) statement, an anti-COVID-19 therapeutic application of the drug 2-deoxy-D...
- Jubilant Pharmova arm completes studies using novel oral formulation of RemdesivirJubilant Pharma has successfully completed "safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India ...
- Jubilant Pharmova surges as company develops Remdesivir oral formHospitals and pharmacists in major cities have reported acute shortage of the drug due to supply constraints and alleged hoarding.
- Oral Covid treatment yields promising trial data: DrugmakersIn January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, incl...
- Rhizen Pharmaceuticals gets USFDA approval for phase one clinical trials for Covid-19 drugThe Switzerland-based firm, which is a clinical-stage oncology-focussed biopharmaceutical company, has received approval for its investigat...
Load More
